Escitalopram and Depression in Elderly Alzheimer's Patients

An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00488670

Enrollment

Registered

2007-06-20

Start date

2010-12-31

Completion date

2011-06-30

Last updated

2011-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder

Keywords

Alzheimer's disease, elderly, open-label, escitalopram

Brief summary

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.

Detailed description

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

Interventions

DRUGEscitalopram

See Detailed Description.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* \> 50 years * Male & female * Alzheimer's disease * Depressive episode

Design outcomes

Primary

Measure	Time frame
Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.	—

Secondary

Measure	Time frame
Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026